Q-omics provides the consensus-scored UBA52P7 profile across patient tissues and cancer cell-line models. UBA52P7 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, UBA52P7 is differentially expressed in 5, with the highest sampling consensus in KIRC. Additionally, UBA52P7 RNA expression shows 6,830 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight STAD, KIRC, and ACC as cancer lineages where UBA52P7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBA52P7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBA52P7 survival associations across molecular data types. UBA52P7 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBA52P7 RNA expression–survival associations across cancer types. High UBA52P7 expression shows unfavorable associations in STAD, ACC and LIHC, but favorable associations in CESC, SKCM and BLCA. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .005). Together, the overview and detailed table identify STAD as the clearest survival context for UBA52P7 RNA expression.
This table summarizes UBA52P7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for UBA52P7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBA52P7 shows lower tumor expression in THCA and BLCA and higher tumor expression in KIRC, LIHC and BRCA. The KIRC box plot shows higher UBA52P7 RNA expression in tumor versus normal tissue (log2 FC = +0.787, t-test p < 0.001).
This table shows molecular features associated with UBA52P7 in patient tissues and cancer cell lines. In patient samples, UBA52P7 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set.
